August 2015 Work Group Recaps:

For results of Data Element Request Forms (DERFs) and External Code Set (ECLs) reviewed see DERF Resolution at http://www.ncpdp.org/members/members_wg_info.aspx?wgid=wgmc.

Work Group 1 Telecommunication

Ballot Adjudication:
- None

DERFs/ECLs Reviewed:
- DERF 001240 was approved.
- DERF 001274 was approved.
- DERF 001278/ECL 000179 was approved.
- DERF 001279 was withdrawn.
- DERF 001280 was pended to the MC Prior Authorization Harmonization Task Group.
- DERF 001303/ECL 000184 was pended to the WG1 Information Reporting Matching Logic for Nx Transactions Sub Task Group.
- DERF 001304/Emergency ECL 000185 was approved.
- DERF 001305/Emergency ECL 000186 was approved.
- DERF 001306/Emergency ECL 000187 was pended to the WG1 Telecommunication FAQ Task Group.
- DERF 001307 was pended to the WG1 Telecommunication FAQ Task Group.
- DERF 001308 was pended to the WG1 Telecommunication FAQ Task Group.
- DERF 001309 was pended to the WG1 Telecommunication FAQ Task Group.
- DERF 001310 was pended to the WG1 Telecommunication FAQ Task Group.

Old Business:
- A HIPAA Standards, Operating Rules, and regulations (HPID/ICD/NPI/EFT/ERA) update was given.
- Use of Quantity Prescribed (46Ø-ET) in the Telecommunication Standard claim billing - Note this field would be required for Part D Schedule II Controlled Substance claims; however the use of this field is not limited to Part D claims only.
  - Telecom D.0 and all versions from that point have been updated (November 2012).
  - 03/2014 NCPDP received a response from HHS to the 03/2013 letter. The change will go through NPRM and Final Rule process.
    - We have asked the industry to have input on the implementation timeframe before the NPRM is published.
    - We have asked for a timeframe of NPRM publication.
- 06/2014 Update: OESS has responded that an NPRM including Quantity Prescribed and SCRIPT electronic prior authorization is going through the review process.
- WG1 Telecommunication FAQ Task Group brought forward a recommendation timeframe for Quantity Prescribed regulation implementation for OESS.
- 07/21/2015 Update from NSG: Our new target for this regulation is early 2016.

Task Groups:
- The Telecommunication FAQ Task Group finalized five questions, four questions are under discussion and three remain in a monitor status. There were three Editorial Guide requests this quarter which were approved.
- The Coordination of Benefits Task Group completed recommendations for Adjudicated Program Type values, and collaborated with the WG9 Part D Supplemental Payment Reporting Task Group and the WG1 Telecommunication FAQ Task Group on questions. A presentation on the COB modifications to the Telecommunication Standard was given to attendees.
• The **Financial Information Reporting (FIR) Task Group** brought forward an FAQ which was approved for the FIR Editorial Document. They will continue working on FAQs, white papers, and the extension of automated FIRs.

• The **Information Reporting Problems Task Group** brought forward two DERFs and developed a worksheet to track the pros and cons of naming N transactions as a HIPAA standard. An application (previously an attestation) was developed for SPAP/ADAP’s use. CMS reviewed the application for additions to their CMS process; however, CMS determined that most of the items in the application were already in the SPAP Template. The end-result will be SPAPs forwarding their Unique Bin/PCN to NCPDP to compare and possibly update records for SPAPs on our SPAP/ADAP Bin/PCN spreadsheet. They are creating a white paper to document best practices for matching N transactions which may result in additional reject codes, an SPAP/ADAP Data Exchange White Paper, and a best practices guide for Part D sponsors to help clean up overlapping OHI. They are also reviewing and updating the COB White Paper and processes when a B1 is reversed and the need to internally reverse the associated N1 prior to receiving a N2 request from the transaction facilitator.

• The **Post Adjudication Task Group** did not meet this quarter.

• The **Definition of a Valid Prescriber Task Group** responded to CMS IFC 6107, brought forward a DERF for a new POS reject code to address MACRA legislation requirements, developed Part D POS hierarchical rules for prescriber validation, collaborated with the WG1 FAQ TG, reviewed CMS guidance documents, and reviewed a WG1 DERF.

• The **Part D Supplemental Payment Reporting Task Group** continues to work on a reject code guide applicable to Medicare Part D N transactions and will develop a FAQ Document.

• The **Eligibility Verification Enhancements Task Group** did not meet.

• The **Transaction ID Task Group** made revisions to the documents for pended DERF 001274.

• The **Benefit Integration Task Group** did not meet this quarter. A small group has been working on creating an XML version of the Dual Book of Records and will begin working on the Single Book of Records next quarter for both a flat file format and XML schema.

• The **Standardized Subrogation Task Group** created a presentation for work group discussion on the pros and cons of naming a Standardized Subrogation standard as a HIPAA adopted standard. The standard will modify the current HIPAA adopted Medicaid Subrogation Standard to a universal format and name the new standard for HIPAA adoption for Medicaid only. The universal format will include Medicare Part D and Commercial subrogation requirements.

**New Business:**

• The WG1 Scope and Goals were approved.

**Work Group 2 Product Identification**

**Task Groups:**

• The **Structure Product Labeling Activities Task Group** tracks the activities of the SPL and offers suggestions to improve access and usability of the FDA Structured Product Label and Electronic Drug Listings. The task group has sent 19 letters to the FDA and approved a letter on storage conditions. The task group will discuss with the FDA the capability to capture actual data elements and not graphs in structured data provided within the SPL.

• The **Product Review and Billing Unit Exception Task Group** is reviewing the exceptions within the Implementation Guide and issues that result from changes to existing products or release of new products. The letter approved by WG2 at the May 2015 WG meeting to Golden State Medical Supply regarding GSMS’s re-use of NDC Core 9 (Labeler Code + Product Code) for products having different active ingredients or strengths was sent and a response received. The response stated
GSMS re-evaluated this practice and decided to stop reassigning the product code to another drug product effective May 1, 2015 and going forward will assign new (not reassigned) product codes under labeler code 60429 or 51407. Sandoz released a new product Glatopa™, their generic version of Copaxone and packaged it with alcohol preps making the Billing Unit=Each which could cause billing issues since the Billing Unit for Copaxone is now BU = mL. Intervention by the WG2 Co-Chairs and a quick response and immediate action by Sandoz resulted in a packaging configuration change for Glatopa™ via the removal of the alcohol swabs. Due to this change, Glatopa™ now has a Billing Unit = mL and the quantity = 1. The task group also reviewed five new QUIC forms and submitted them to WG2 for final adjudication.

- The **NCPDP Product Identification Standard Task Group** developed the NCPDP Product Identifiers Standard Implementation Guide and have successfully balloted version 1.0 and 1.1 of that standard. DERF 1281 to add clarifying verbiage to the standard was submitted by the task group for review at the May 2015 WG meeting. The DERF was approved and the Product Identifiers Standard Implementation Guide Version 1.2 will be balloted at the end of the August 2015 WG meetings.

- The **SPL REMS Requirements Task Group** is to gather the data needed to develop a template for pharmaceutical manufacturers to use in electronic submission of all the components for risk evaluation and mitigation strategies (REMS) drugs to a central repository (DailyMed) via FDA’s Structured Product Labeling system. On September 24, 2015 to mark the 10th Anniversary of DailyMed, NLM has invited NCPDP (Ed Millikan, Gerry McEvoy, and Adam Kroetsch) to present on the current status and direction of SPL for REMS as one of 2 keynote topics for the 3rd Annual DailyMed/RxNorm Jamboree Workshop. On October 5, 2015, FDA will be holding a public meeting on REMS: Understanding and evaluating their impact on the health care delivery system and patient access. Michele Davidson (WG11) has been invited by FDA to serve as a panelist at this meeting. The main questions to be considered are 1) how to minimize the burden of REMS on the healthcare system and on patient access and 2) how to improve the quality and effectiveness of methods used to evaluate REMS burden on the healthcare system and on patient access.

- The **Dates Associated with Pharmaceutical Products Task Group** investigates definition inconsistencies, involves government agencies to make them aware of the issues, and provides education on the importance via a white paper or other means. The white paper is nearly completed and will be submitted for review at the November WG meetings.

- The **Naming Standards for Drugs, Biologics and Biosimilars Task Group** reported the Amgen patent violation claim against Sandoz was denied. The task group sent a letter to USP on May 18th on the *Nonproprietary Naming of Biologics, Biosimilars, and Interchangeable Biologics: Zarxio® (filgrastim)* and followed up with a similar letter to the United States Adopted Names Council (USAN). The USP and USAN letters are on the NCPDP website at [http://www.ncpdp.org/Resources/Hot-Topics](http://www.ncpdp.org/Resources/Hot-Topics). The task group was contacted by the VA who is struggling to determine how to represent filgrastim for physician pick lists and patient container labels. We encouraged the VA to remain steadfast in their communication with FDA regarding patient safety issues and are working on meeting with someone from the central office of the VA.

- The **Review of Appendix B Reference Code Qualifiers Task Group** completed the review of definitions of existing product identifiers for accuracy, updated Appendix B and frontal matter of the ECL and submitted a DERF that was approved at the May 2015 WG meetings. The task group was disbanded.

- The **Application of the Billing Unit Standard Clarification Task Group** continues to make progress in identifying the rationale used to determine the billing unit from past QUIC forms/products reviews and is capturing the rationale/reasons for those decisions. Once the forms have been reviewed and the results compiled, a guidance document will be written.
• An update on the joint **WG11 and WG2 Drug Description Task Group** was not provided as they had not met.
• An update on the WG9 and WG2 Unbreakable Packages Task Group was provided. See WG9 meeting minutes.

**New Business:**
• **QUIC Form Review:**
  - QUIC #201513 Liquid Hope, UPC 57858-0004-00
    **BU=gm,** **Package Size=341** per Section 4.2.3 of the BUS
  - QUIC #201514 Kanuma 20mg/10mL, NDC 69334-0721-01
    **BU=ml with a quantity of 10 ml** per Section 5.2.2 of the BUS
  - QUIC #201515 DEFINITY 1.1 MG/ML VIAL NDCs 11994-011-01; 11994-011-04; 11994-011-16
    **BU=ml with a vial quantity of 2 ml** per Section 5.2.2 of the BUS
    - NDC (11994-011-01), vial (2mL x 1 = 2 mL)
    - NDC (11994-011-04), 4 vial kit (2mL x 4 = 8 mL)
    - NDC (11994-011-16), 16 vial kit (2mL x 16 = 32 mL)
  - QUIC #201516 Clindess NDCs 64011012408, 21695085805, 45802004201
  - QUIC #201517 Gynazole NDCs 64011024601, 54868483800, 64011000108, 54569545200, 45802039601 (yet to be released)
    QUIC forms adjudicated together.
    **BU=5 gm on the active NDCs 64011024601 (Gynazole) and 45802004201 (Clindesse) and any new products released in the future per FAQ 7.34 of the BUS. To minimize disruption in the market place, the older products for Clindesse (NDCs 21695085805 and 64011012408) and Gynazole (NDCs 54868483800, 64011000108 and 54569545200) with obsolete dates will not change billing units and will remain with a BU=5.8 gm**
• **WG2 Scope and Goals were approved.**

**Work Group 3 Standard Identifiers**

**DERFs/ECLs Reviewed:**
• DERF 001247/ECL 000175 – recommendation to MC to approve the DERF/ECL with modifications.
• DERF 001311 – approved with modifications.

**Task Groups:**
• The **Pharmacy and/or Combination ID Card Task Group** submitted DERF 001311 referenced above.
• The **Health Plan ID (HPID) Task Group** is on hold until CMS responds to NCVHS recommendations regarding the use of HPID in transactions.

**New Business:**
• The WG3 Scope and Goals were approved.

**Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards**

**Old Business:**
• A summary of each task group’s meeting history for 2014/2015 was reviewed for the purpose of thinking about how the task group is contributing to the mission of the Work Group and what the goal of each task group should be for the coming year in order to successfully contribute to that mission.

**Task Groups:**
• The **Rebate Reference Guide Task Group** did not meet this quarter.
• The Medical Rebate Standard Task Group did not meet this quarter.
• The Medicaid Drug Rebate Program Task Group reviewed portions of CMS-2390-P, Medicaid and Children’s Health Insurance Program (CHIP) Programs; Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability related to the proposal to add encounter data standards to be incorporated in all managed care contracts.
• The Rebate Standard Update Task Group reviewed the known issues on linking formulary to utilization data in order to understand the critical issues and what is still needed. Work will continue next quarter.
  • Specialty Pharmacy Data Exchange Sub-Task Group has begun initial work on identifying the fields necessary for the data exchange. That work will continue as well as defining the objectives and desired outcomes between these trading partners.
• The Regulatory Tracking/Pedigree Task Group did not meet this quarter.
• The Formulary Management Survey Task Group has drafted two surveys (manufacturer and payer/processor) with the goal being to understand the current scope, process and challenges of formulary validation for commercial and Part D contracts. The surveys will be finalized during the next quarter.
• Update from WG9 OIG Report OEI 05-12-00540 Task Group. See WG9 minutes.

New Business:
• The WG7 Scope and Goals were approved.
• A detailed overview of the Manufacturer Rebate Utilization File was presented.
• The Work Group discussed different approaches that could be used to obtain input from users of the standard related to what improvements could be made resulting in broader adoption.

Work Group 9 Government Programs
DERFs/ECLs Reviewed:
• DERF 001312/Emergency ECL 000188 – recommendation to MC to approve the DERF/Emergency ECL as modified by the Work Group.

Task Groups:
• The Prescription Monitoring Program (PMP) Task Group presented updated information for states that have prescription monitoring programs. The updated tracking document will be published.
• The 340B Task Group met to discuss a request received by the WG1 Information Reporting Task Group to name the N transaction as a transaction under HIPAA. An overview of the HIPAA process was provided to the task group. At this time, the task group is not recommending the transaction be named in HIPAA.
• The Medicare Part B Claim Billing for Dual Eligibles Task Group did not meet this quarter.
• The Health Insurance Exchange/Marketplace Task Group did not meet this quarter.
• The Medicaid Subrogation FAQ Task Group did not meet as no new questions were received.
• The Medicare Part D FAQ Task Group brought forward 13 questions and responses for review. Twelve questions were approved, one question was pended to the Task Group for modification and one question will not be published. The Medicare Part D FAQ document will be updated and published. WG9 also approved the Medicare Part D Post Point-of-Sale Claim Adjustments guidance document.
• WG9/WG2 Unbreakable Package Joint Task Group presented a draft letter to CMS which will recommend a NCPDP definition for unbreakable package. WG 9 approved the letter.
• The **Supplemental Payer Part D Reconciliation Standardization Task Group** did not meet this quarter.

• The **Hospice Task Group** continued work on a retrospective reconciliation file for use between Hospice and the Part D Sponsor/Processor. Two questions/responses were presented and approved by WG9. These will be added to the Medicare Part D FAQ document. The task group also submitted DERF 001312/Emergency ECL 000188 referenced above.

• The **Standardized Fraud, Waste and Abuse Training Attestation Task Group** revised the Standardized FWA Training Attestation document to include CMS' June 17, 2015 update. A copy of the attestation form was submitted to CMS with a request that CMS acknowledge that the document contains all required elements. CMS stated that the document did not accurately contain all elements of FWA and it overreached by including General Compliance with FWA. As such CMS is not willing to make any statement about the document at this time. The task group participants have been asked to discuss this issue within their organizations and provide information on the next call.

• The **OIG Report OEI 05-12-00540 Task Group** continued work on the list of solutions. A survey is being developed for distribution to the task group to assist in ranking and prioritizing the solutions. Due to the amount of detail provided in the solutions document, the task group proposed a separate webinar be scheduled to review solutions prior to distributing the survey. The survey will be finalized during the next quarter.

• Received updates from **WG1 Coordination of Benefits, WG1 Definition of a Valid Prescriber** and **WG1 Standardization Subrogation Task Groups**. See WG1 minutes.

**New Business:**

• **WG9 Task Group Realignment**
  - Work Group Reporting Changes
    - WG1 Financial Information Reporting (FIR) Task Group will report to WG9
  - Disbanded Task Groups/Sub Task Groups
    - WG9 Medicare Part B Claim Billing for Dual Eligibles Task Group
    - WG9 LTC (Long Term Care) CII Dispensing Sub Task Group
    - WG9 CMS Part D LTC Dispensing & Impact to Other Payer Sub Task Group
    - WG9 Data Sharing of Over-Utilizers Sub Task Group
  - Status/Name Change
    - WG9 Medicare Prescription Drug Event (PDE) Sub Task Group
  - Name Change only
    - WG9 Medicare Standardized Fraud, Waste and Abuse Training Attestation Task Group

• **WG9 Scope and Goals were approved.**

• **WG9 received a Legislative update.**

**Work Group 10 Professional Pharmacy Services**

**Task Group Reports:**

• The **MTM Communications Task Group** continues to develop new functionality using the CCDA release 2. Currently under development are the specifications for a pharmacy longitudinal care plan.
• The **Acetaminophen Best Practices Hospital Safety Sub-Task Group** is completing extensive referencing in the *NCPDP Recommendations for Dose Accumulation Monitoring in the Inpatient Setting: Acetaminophen Case Model* white paper. Planning and development of the press release for the document is underway. Publication target date is mid-September.

• **WG11 Specialty Requirements for ePrescribing Task Group** is continuing identification of other elements that are needed but not exchanged electronically and develop approach to support electronic exchange. Discuss ways to communicate recommendations (pending approval of ballot).

New Business:
• **WG10 Scope and Goals** were approved with modification.
• **Scope and Goals Modernization Task Group** was formed to develop future modifications of the Scope and Goals to reflect the changing role of the pharmacist as a provider of healthcare services.
• Pamela Schweitzer, RPh, PharmD and USPHS Chief Professional Officer, Pharmacy provided a brief overview of federal initiatives related to pharmacy and pharmacists as providers.

Work Group 11 ePrescribing & Related Transactions

Ballot Adjudication:
• Ballot WG110065R for the Formulary and Benefit Standard is considered a valid ballot having received the required 60+% of Consensus Group votes and 75% approval rating. No new written comments were received. See Letter Ballot Comment spreadsheet for the ballot results. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs Reviewed:
• DERF 001271 was approved as modified by the task group.
• DERF 001288 was approved as modified by the task group.
• DERF 001290 was approved as modified by the task group.
• DERF 001300 was approved as modified by the task group.
• DERF 001313/ECL 189 was recommended for approval.
• DERF 001314 was approved.
• DERF 001315 was approved as modified by the work group.
• DERF 001316 was withdrawn by the submitter.
• DERF 001317 was approved as modified by the work group.
• DERF 001318 was approved.
• DERF 001319 was approved.
• DERF 001320 was approved.
• DERF 001321 was approved.
• DERF 001322 was approved.
• DERF 001323 was withdrawn by the submitter.
• DERF 001326 was approved.

All DERFS approved for the Formulary & Benefit Standard will be held for ballot until January 2016.

Old Business:
• Reviewed timeline for requesting the next version of the SCRIPT Standard in regulation. The version to be requested will be the one published in January 2016.
• Industry updates were provided on NCVHS Subcommittee on Standards, CMS (eprescribing), and DEA eprescribing for controlled substances and implementation activities.

Task Groups:
• The **Formulary and Benefit Task Group** brought forward DERFs 001271, 001300, 001316, 001317, 001318.
• **XML Task Group** reviewed submitted DERFs and brought forward recommendations.
• **NCPDP/HL7 Pharmacist Functional Profile Task Group** is developing EHR-S R2 functional profiles for the pharmacy practice specific setting.
• **WG11 Electronic Prescribing Best Practices Task Group** provided recommendations for the SCRIPT Implementation Recommendations document on new terms for NCI Thesaurus. They also brought forward DERFs 001313/ECL 189, 001315 and 001323.
• **WG14 LTPAC ePrescribing Task Group** brought forward DERFS 001321 and 001322. They continue to work on electronic prescribing issues related to the long term and post-acute care settings.
• **REMS and ePrescribing Task Group** brought forward DERF 001288.
• The **Electronic Prior Authorization Workflow to Transactions Task Group** brought forth DERFs 001314, 001319, 001320 and 001326. They also brought forth best practices for attachments in ePA to be added to the SCRIPT Implementation Recommendations document.
• The **WG11/2 Joint Drug Description Task Group** did not meet.
• The **Meaningful Use and NIST Test Methods for ePrescribing Task** did not meet.
• **Implementation of Structured Sig Task Group** provided recommendations for the SCRIPT Implementation Recommendations document on 13 additional Sigs.
• **Specialty Requirements for ePrescribing Task Group** brought forward DERF 001290 to support ePrescribing for wound care.

New Business:
• WG11 Scope and Goals were approved.
• Approved a new task group for the Harmonization of Prescribing and Dispensing Units. It will be a joint WG1 Telecommunication, WG2 Product Identifiers and WG11 ePrescribing and Related Transactions task group housed in WG11.

**WG14 Long Term and Post Acute Care (LTPAC)**

Old Business:
• Industry/Regulatory updates were provided which included HIPAA, NCVHS, and Meaningful Use

Task Group Reports:
• The **ePrescribing Task Group** presented their proposed modifications for electronic prescribing for an IV administration solution.
• The **LTPAC Current Billing Issues Task Group** is looking at the NCPDP Telecommunication Standard to determine if the long term and post-acute care setting needs are met. They discussed ICD-10 Guidance and Backup Pharmacy issues.
• Received updates from the **WG9 Hospice Task Group** and the **Medicare Part D FAQ Task Group**.

New Business:
• WG14 Scope and Goals were approved.

**Work Group 16 Property & Casualty/Workers Compensation**

DERFs/ECLs Reviewed:
• DERF 001278/ECL 000179 was reviewed by WG with recommendation to MC to approve the DERF/ECL with modifications.
• DERF 001307 was pended by WG1 to the WG1 FAQ Task Group for review. It was reviewed by WG16 with suggestions for clarification to WG1 FAQ.
• DERF 001308 was pended by WG1 to the WG1 FAQ Task Group for review. Since this DERF is to replace a workaround developed with the WG1 FAQ Task Group, the original FAQ will be added to the documentation.

• DERF 001309 was pended by WG1 to the WG1 FAQ Task Group for review. This DERF is to add an existing field on the WC/PC UCF to the Telecommunication Standard and replace the current value table.

• DERF 001310 was pended by WG1 to the WG1 FAQ Task Group for review. Examples of use of the special jurisdiction requirements will be added to the documentation for WG1 FAQ review.

Task Group Reports:
• The Legislative/Regulatory Monitoring and Education Task Group provided an update on state regulatory and legislative initiatives affecting Workers’ Compensation programs.

• The Billing and State Reporting Task Group provided an update regarding states moving to adopt regulations for e-billing, standard paper billing and EDI reporting. Letters regarding proposed rules were sent to Florida, Texas and New Mexico.

• An update on discussion by the MC Real Time Pharmacy Benefit Inquiry Task regarding inclusion of a workers’ compensation use case was provided.

New Business:
• WG16 Scope and Goals were approved with modification.

Work Group 45 External Standards Assessment, Harmonization and Implementation Guidance

Old Business:
• Industry updates were provided for WEDI, ASC X12, and CAQH CORE.

Task Groups:
• The Document Revision Task Group reviewed two new CARC for the mapping document and a revision to the NCPDP Procedure via the Collaborative Workspace. Neither of the CARCs will be used by pharmacy. The change to the mapping document was approved by the work group and will be go through the inter SDO process.

• The 834/835 FAQ Task Group received no new questions.

• A DSMO Task Group received no DSMO requests for review.

• CAQH CORE Task Group did not meet.

• An update was provided on the WG1 FAQ Task Group discussion of the Louisiana Provider fee.

• An update was provided on the MC UDI Task Group.

New Business:
• WG45 Scope and Goals were approved.

MC Maintenance and Control

Ballot Adjudication:
• Ballot WG110065R for the Formulary and Benefit Standard is considered a valid ballot having received the required 60+% of Consensus Group votes and 75% approval rating. No new written comments were received. See Letter Ballot Comment spreadsheet for the ballot results. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs Reviewed:
• 33 new and pended DERFs/ECLs were reviewed (see WG1, WG3, WG9, WG11 above).

• MC reviewed:
  o DERF 001324 which was approved.
  o DERF 001325 which was withdrawn.
The DERFs approved May and at this meeting will result in five ballots for the August 2015 ballot period:
- WG010066 for Telecommunication vE8
- WG010067 for Batch Standard v13
- WG020007 for Product Identifier Standard v1.2
- **WG100007-WG100008** for the Structured and Codified Sig v21
- WG110066 for SCRIPT, Specialized and XML v2016xx#

The DERFs approved at the May 2015 meeting and this meeting will result in the following implementation guides for Board approval:
- Operating Rules for Connectivity v1.2
- Pharmacy And/Or Combo ID Card Implementation Guide v4.3

The Formulary & Benefit DERFs approved at the May 2015 and August 2015 Work Group meetings will be held for the February 2016 ballot period.

**Old Business:**
- Updates are available in the MC May 2015 download file:
  - HIPAA
  - NCPDP Legislative/Regulatory Activities

**Task Groups:**
- The **Education/Legislation and Regulations Task Group** will meet to provide comments on the NPRMs for Certification and Test Procedures.
- The **PDMP White Paper Task Group** was disbanded. Members are encouraged to join the WG9 Prescription Monitoring Task Group.
- The **Unique Device Identifier (UDI) Task Group** presented DERF 001325 which was withdrawn.
- The **Real Time Benefit Check Task Group** continues working on use cases. They will have dedicated upcoming calls to discuss open questions. See the NCPDP Collaborative for more information.
- The **Prior Authorization Harmonization Task Group** continues working on the harmonization of the prior authorization fields across the NCPDP Standards. They will bring forth a DERF at the November Work Group meeting.

**Project Development Form:**
- New Project Development Form 000039 recommendations were approved by the Standardization Co-Chairs and the NCPDP Board of Trustees. The API Task Group was formed to update the NCPDP Connectivity Standard.
- New Project Development Form 00040 was reviewed and pended for additional information from the submitter.

**New Business:**
- The attendees received recaps of each Work Group’s activities.
- MC Scope and Goals were approved.